Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.

Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE, Werba G, Zhang K, Guo Y, Li Q, Akkad N, Lall S, Wadowski B, Gutierrez J, Kochen Rossi JA, Herzog JW, Diskin B, Torres-Hernandez A, Leinwand J, Wang W, Taunk PS, Savadkar S, Janal M, Saxena A, Li X, Cohen D, Sartor RB, Saxena D, Miller G.

Cancer Discov. 2018 Apr;8(4):403-416. doi: 10.1158/2159-8290.CD-17-1134. Epub 2018 Mar 22.

2.

The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo M, Ochi A, Zambirinis CP, Pansari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G.

Nature. 2016 Apr 14;532(7598):245-9. doi: 10.1038/nature17403. Epub 2016 Apr 6.

3.

NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma.

Daley D, Mani VR, Mohan N, Akkad N, Pandian GSDB, Savadkar S, Lee KB, Torres-Hernandez A, Aykut B, Diskin B, Wang W, Farooq MS, Mahmud AI, Werba G, Morales EJ, Lall S, Wadowski BJ, Rubin AG, Berman ME, Narayanan R, Hundeyin M, Miller G.

J Exp Med. 2017 Jun 5;214(6):1711-1724. doi: 10.1084/jem.20161707. Epub 2017 Apr 25.

4.

Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.

Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, Lee KB, Zambirinis CP, Pandian GSB, Savadkar S, Torres-Hernandez A, Nayak S, Wang D, Hundeyin M, Diskin B, Aykut B, Werba G, Barilla RM, Rodriguez R, Chang S, Gardner L, Mahal LK, Ueberheide B, Miller G.

Nat Med. 2017 May;23(5):556-567. doi: 10.1038/nm.4314. Epub 2017 Apr 10.

5.

T-cell programming in pancreatic adenocarcinoma: a review.

Seo YD, Pillarisetty VG.

Cancer Gene Ther. 2017 Mar;24(3):106-113. doi: 10.1038/cgt.2016.66. Epub 2016 Dec 2. Review.

PMID:
27910859
6.

Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR.

Gut. 2014 Nov;63(11):1769-81. doi: 10.1136/gutjnl-2013-306271. Epub 2014 Feb 20.

7.

Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling.

Riquelme E, Maitra A, McAllister F.

Cancer Discov. 2018 Apr;8(4):386-388. doi: 10.1158/2159-8290.CD-18-0123.

8.

Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice.

Seifert L, Werba G, Tiwari S, Giao Ly NN, Nguy S, Alothman S, Alqunaibit D, Avanzi A, Daley D, Barilla R, Tippens D, Torres-Hernandez A, Hundeyin M, Mani VR, Hajdu C, Pellicciotta I, Oh P, Du K, Miller G.

Gastroenterology. 2016 Jun;150(7):1659-1672.e5. doi: 10.1053/j.gastro.2016.02.070. Epub 2016 Mar 3.

9.

Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.

Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, Schmid MC, Sun P, Mose E, Bouvet M, Lowy AM, Valasek MA, Sasik R, Novelli F, Hirsch E, Varner JA.

Cancer Discov. 2016 Aug;6(8):870-85. doi: 10.1158/2159-8290.CD-15-1346. Epub 2016 May 13.

10.

IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer.

Mirlekar B, Michaud D, Searcy R, Greene K, Pylayeva-Gupta Y.

Cancer Immunol Res. 2018 Sep;6(9):1014-1024. doi: 10.1158/2326-6066.CIR-17-0710. Epub 2018 Jul 6.

PMID:
29980536
11.

γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation.

Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VRK, Avanzi A, Tippens D, Narayanan R, Jang JE, Newman E, Pillarisetty VG, Dustin ML, Bar-Sagi D, Hajdu C, Miller G.

Cell. 2016 Sep 8;166(6):1485-1499.e15. doi: 10.1016/j.cell.2016.07.046. Epub 2016 Aug 25.

12.

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer.

Balli D, Rech AJ, Stanger BZ, Vonderheide RH.

Clin Cancer Res. 2017 Jun 15;23(12):3129-3138. doi: 10.1158/1078-0432.CCR-16-2128. Epub 2016 Dec 22.

13.

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.

Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G.

Cancer Cell. 2018 Nov 12;34(5):757-774.e7. doi: 10.1016/j.ccell.2018.10.006.

PMID:
30423296
14.

Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma.

Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG.

Clin Transl Med. 2019 Apr 1;8(1):10. doi: 10.1186/s40169-019-0226-9. Review.

PMID:
30931508
15.

Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.

Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VG.

PLoS One. 2014 May 2;9(5):e96565. doi: 10.1371/journal.pone.0096565. eCollection 2014.

16.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. doi: 10.1073/pnas.1320318110. Epub 2013 Nov 25.

17.

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.

Martinez-Bosch N, Vinaixa J, Navarro P.

Cancers (Basel). 2018 Jan 3;10(1). pii: E6. doi: 10.3390/cancers10010006. Review.

18.

The Microbiome and Pancreatic Cancer: An Evidence-based Association?

Archibugi L, Signoretti M, Capurso G.

J Clin Gastroenterol. 2018 Nov/Dec;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition & Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S82-S85. doi: 10.1097/MCG.0000000000001092.

PMID:
30001289
19.

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L.

J Immunother. 2015 Jan;38(1):1-11. doi: 10.1097/CJI.0000000000000062.

20.

Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features.

Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, Quertinmont E, Svrcek M, Elarouci N, Iovanna J, Franchimont D, Verset L, Galdon MG, Devière J, de Reyniès A, Laurent-Puig P, Van Laethem JL, Bachet JB, Maréchal R.

Gastroenterology. 2018 Dec;155(6):1999-2013.e3. doi: 10.1053/j.gastro.2018.08.033. Epub 2018 Aug 27.

PMID:
30165049

Supplemental Content

Support Center